Ibotta, Inc.
NYSE:IBTASoftware - Application
-$0.19 today
- Market cap
- $1.16B
- Beta
- -0.58
- P/E (TTM)
- -96.1
- EPS (TTM)
- -$0.30
Volume 0.45M
Average 0.22M
IBTA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Ibotta, Inc.NYSE: IBTA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $14.5M fell 19.7% year over year, behind the -15.0% change in trailing-twelve-month research & development. Sequentially, it rose 1.8% from the prior quarter. Over 3 fiscal years it compounded at +12.8% a year.
Context
- Research & development amounted to 17.8% of revenue in FY2025, up 0.6 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -19.7% toward the trailing-twelve-month pace of -15.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 61.08M USD
- Year-over-year change
- -3.5%
- 3-year CAGR
- +12.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 61.08M | -3.5% |
| FY2024 | 2024-12-31 | 63.27M | +26.6% |
| FY2023 | 2023-12-31 | 50M | +17.5% |
| FY2022 | 2022-12-31 | 42.56M | — |
Research & Development vs competitors
How IBTA compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -15.0% is the 7th highest of 9, against a peer median of +1.4%.
- Research & development amounts to 16.9% of revenue for IBTA, versus a peer median of 19.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | CN¥1.01B CNY | +28.6% | -1.5% | 7.9% | |
| LTM Mar 2026 | $68.47M USD | +0.1% | -2.2% | 19.5% | |
| LTM Mar 2026 | $66.07M USD | +18.3% | +3.8% | 26.7% | |
| LTM Mar 2026 | $57.52M USD | -15.0% | +12.8% | 16.9% | |
| LTM Mar 2026 | $52.17M USD | +11.2% | +26.5% | 20.8% | |
| LTM Mar 2026 | $40.48M USD | +2.6% | -10.5% | 7.2% | |
| LTM Mar 2026 | $34.74M USD | -11.9% | -38.0% | 27.2% | |
| LTM Mar 2026 | $30.97M USD | -49.2% | — | 28.6% | |
| LTM Mar 2026 | $2.65M USD | — | — | 2.8% | |
| LTM Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding IBTA) | — | +1.4% | -1.8% | 19.5% | |
Competitors are the stored peer set for IBTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 210.7M | 320.04M | 367.25M | 342.39M |
| Cost of Revenue | 49.22M | 47.65M | 50.12M | 74.97M |
| Gross Profit | 161.48M | 272.38M | 317.13M | 267.42M |
| Gross Margin | 76.6% | 85.1% | 86.4% | 78.1% |
| Research & Development | 42.56M | 50M | 63.27M | 61.08M |
| Selling, General & Admin | 159.23M | 166.39M | 221.95M | 207.18M |
| Operating Expenses | 201.79M | 216.39M | 289.21M | 265.77M |
| Depreciation & Amortization | 6.32M | 6.66M | 8.08M | 8.32M |
| EBITDA | (42.97M) | 57.6M | 32.58M | 18.17M |
| EBITDA Margin | -20.4% | 18.0% | 8.9% | 5.3% |
| Operating Income | (40.31M) | 56M | 27.93M | 1.66M |
| Operating Margin | -19.1% | 17.5% | 7.6% | 0.5% |
| Interest Income | 0 | 0 | 9.41M | 10.78M |
| Interest Expense | 5.31M | 6.88M | 0 | 0 |
| Other Income / Expenses | (14.29M) | (11.95M) | (3.43M) | 8.19M |
| Income Before Tax | (54.6M) | 44.05M | 24.5M | 9.85M |
| Pre-Tax Margin | -25.9% | 13.8% | 6.7% | 2.9% |
| Income Tax Expense | 262K | 5.93M | (44.25M) | 6.27M |
| Net Income | (54.86M) | 38.12M | 68.74M | 3.58M |
| Net Margin | -26.0% | 11.9% | 18.7% | 1.0% |
| EPS (Basic) | (1.81) | 1.26 | 2.85 | 0.13 |
| EPS (Diluted) | (1.81) | 1.26 | 2.56 | 0.12 |
| Weighted Avg Shares | 30.24M | 30.24M | 24.12M | 28.37M |
| Weighted Avg Shares (Diluted) | 30.24M | 30.24M | 26.86M | 30.1M |
Ibotta, Inc.
NYSE:IBTA
Intrinsic Alpha fair value
Locked
Current Price
$56.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.